<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3485">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473274</url>
  </required_header>
  <id_info>
    <org_study_id>IRB20-042</org_study_id>
    <nct_id>NCT04473274</nct_id>
  </id_info>
  <brief_title>GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study</brief_title>
  <acronym>GOTCHA</acronym>
  <official_title>GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samaritan Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samaritan Health Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pioglitazone is an approved anti-hyperglycemic medication and is thought to have
      anti-inflammatory properties. This study seeks to gather safety and tolerability data related
      to pioglitazone when given to patients who require hospital admission for confirmed positive
      COVID-19 infections with elevated blood sugar levels as compared to patients who did not
      receive pioglitazone during their hospitalization for COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Matching cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events outcomes without attribution</measure>
    <time_frame>Baseline, until 30 days after last dose</time_frame>
    <description>Number and type of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events attributable</measure>
    <time_frame>Baseline, until 30 days after last dose</time_frame>
    <description>Number and type of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>Baseline, until 30 days after last dose</time_frame>
    <description>Disease severity as measured by 7 point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of treatment</measure>
    <time_frame>Baseline, until 30 days after last dose</time_frame>
    <description>Type of oxygen support treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>d-Dimer</measure>
    <time_frame>Baseline, until 30 days after last dose</time_frame>
    <description>Change from Baseline of d-Dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C Reactive Protein</measure>
    <time_frame>Baseline, until 30 days after last dose</time_frame>
    <description>Change from Baseline of CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ferritin</measure>
    <time_frame>Baseline, until 30 days after last dose</time_frame>
    <description>Change from Baseline of Ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase</measure>
    <time_frame>Baseline, until 30 days after last dose</time_frame>
    <description>Change from Baseline of Lactate dehydrogenase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A1c</measure>
    <time_frame>Baseline, until 30 days after last dose</time_frame>
    <description>Change from Baseline of A1c</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Pioglitazone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pioglitazone 15mg to 30mg daily oral or enteral during hospitalization for up to 30 days in addition to standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching cohort group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Receive pioglitazone 15mg - 30mg daily</description>
    <arm_group_label>Pioglitazone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Laboratory confirmed COVID-19 requiring hospitalization

          -  A1c greater than 5.6% as measured in the last 30 days

          -  Women of child-bearing potential who agree to use highly effective method of
             contraception (defined as either abstinence, condom, diaphragm, and/or oral or
             injected hormonal contraception) during dosing and for 30 days after last dose

          -  MRSA PCR screen negative

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  Congestive Heart Failure all classes (NYHA Class I, II, III or IV)

          -  Liver enzyme ALT greater than 2.5 times upper limit of normal

          -  End stage renal disease

          -  Hypersensitivity or allergy to a TZD (thiazolidinedione)

          -  Active bladder cancer

          -  Currently taking a beta blocker, a CYP2C8 inhibitor or inducer such as gemfibrozil or
             rifampin, a TZD

          -  Other current or historical illness that in the opinion of the investigator at
             attending provider would interfere with the subject's ability to complete the study or
             make it not in the best interest of the subject to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Delmonaco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samaritan Health Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Delmonaco</last_name>
    <phone>541-768-5111</phone>
    <email>delmonacochrq@samhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anthony Franklin</last_name>
    <phone>541-768-4351</phone>
    <email>anfranklin@samhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Good Samaritan Hospital Corvallis</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Delmonaco, MD</last_name>
      <phone>541-768-5111</phone>
      <email>delmonaco@samhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Anthony Franklin</last_name>
      <phone>541-768-4351</phone>
      <email>anfranklin@samhealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

